NewAmsterdam Pharma Company N.V. (NAMS) total liabilities

Total liabilities · fiscal 2025
$85.85M

NewAmsterdam Pharma Company N.V. (NAMS) had total liabilities of $85.85M at the end of fiscal 2025 (December 31, 2025). That is 19.9% lower than the $107.12M of fiscal 2024. Figures as of 18 Nov 2026, 23:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$85.85M
Change on fiscal 2024
−19.9%
Highest on record
$107.12Mfiscal 2024
Lowest on record
$48.43Mfiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

NewAmsterdam Pharma Company N.V. total liabilities, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $107.12M in fiscal 2024 and the lowest $48.43M in fiscal 2022.

History · 4 fiscal years

Total liabilities by fiscal year

NewAmsterdam Pharma Company N.V. total liabilities, year by year

NewAmsterdam Pharma Company N.V. (NAMS) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$85.85M 19.9% down
2024$107.12M 82.5% up
2023$58.70M 21.2% up
2022$48.43M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

More on NAMS

NewAmsterdam Pharma Company N.V., figure by figure

NewAmsterdam Pharma Company N.V. (NAMS) overview: price, valuation and scorecard

NewAmsterdam Pharma Company N.V. total liabilities: questions and answers

How large are NewAmsterdam Pharma Company N.V.'s total liabilities?

NewAmsterdam Pharma Company N.V. (NAMS) had total liabilities of $85.85M at the end of fiscal 2025 (December 31, 2025). That is 19.9% lower than the $107.12M of fiscal 2024.

What are the highest and lowest total liabilities figures on record for NewAmsterdam Pharma Company N.V.?

Across the 4 fiscal years on record (2022–2025), the highest was $107.12M in fiscal 2024 and the lowest $48.43M in fiscal 2022.

How is NewAmsterdam Pharma Company N.V.'s total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For NewAmsterdam Pharma Company N.V. it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “NewAmsterdam Pharma Company N.V. (NAMS) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/NAMS/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.